Other drugmakers could still “win” the race in the rapidly growing obesity market dominated by Novo Nordisk and Eli Lilly, according to the chief executive of biotech company Zealand Pharma.
The claim by Adam Steensberg follows a 100 per cent surge in the company’s share price in the past year as investors bought the stock thanks to the potential of its anti-obesity drugs.
Zealand’s products in development will have to compete with the popular Wegovy and Zepbound drugs already on the market and made by Novo Nordisk and Eli Lilly respectively, which suppress appetite.
您已閱讀14%（572字），剩餘86%（3432字）包含更多重要資訊，訂閱以繼續探索完整內容，並享受更多專屬服務。